CCN2 and diabetic kidney disease: Dapagliflozin can inhibit the nuclear translocation of YAP/TAZ, thereby reducing the transcription of its downstream pro-fibrotic target genes connective tissue growth factor (CTGF) to improve DKD fibrosis (Table 3) (Feng et al., 2023).